| [1］CrossRef PC，Garcia R，Angiolillo DJ，et al.Platelet P2Y12 Receptor Inhibition［J］.Circ J，2010，74(4)：597-607. [2］Jennings LK，Saucedo JF.Autiplatelet and anticoagulant agents：key differences in mechanisms of action，clinical application，and therapeutic benefit in patients with non-ST-segment-alevation acute coronary syndromes［J］.Curr Opin Cardiol，2008，23(4)：302-308. [3］Meadows TA，Bhatt DL.CIinical aspects of platelet inhibitors and thrombus formation［J］.Circ Res，2007，100(9)：1261-1275. [4］Dorsam RT，Kunapuli SP.Central role of the P2Y12 receptor in platelet activation［J］.J Clin Invest，2004，113(3)：340-345. [5］van Giezen JJJ，Humphries RG.Preclinical and clinical studies with selective reversible direct P2Y12 antagonists［J］.Sem Thromb Haemost，2005，31：195-204. [6］Angiolillo DJ，Ueno M.Optimizing platelet inhibition in clopidogrel poor metabolizers：therapeutic options and practical considerations［J］.J Am Coll Cardiol Cardiovasc Interv，2011，4：411-414. [7］Wallentin L，Becker RC，Budaj A，et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes［J］.N Engl J Med，2009，361：1045-1057. [8］Steg PG，James SK，Atar D，et al.ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation［J］.Eur Heart J，2012，33(20)：2569-2619. [9］中华医学会心血管病学分会介入心脏病学组，中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南2012(简本)［J］.中华危重症医学杂志(电子版)，2012，5(3)：18-26. [10］Tricoci P，Huang Z，Held C，et al.Thrombin-receptor antagonist vorapaxar in acute coronary syndromes［J］.N Engl J Med，2012，366：20-33. [11］Tello-Montoliu A，Jover E，Rivera J，et al.New perspectives in antiplatelet therapy［J］.Curr Med Chem，2012，19：406-427. |
